Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials

Pierfranco Conte, Alessandra Gennari, Valentina Guarneri, Elisabetta Landucci, Sara Donati, Barbara Salvadori, Carmelo Bengala, Cimzia Orlandini, Editta Baldini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Doxorubicinlpaclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing doxorubicin with epirubicin (Ellence), a less cardiotoxic analog, produced an objective response rate of 84%, but with a low rate of cardiotoxicity. A careful cardiac monitoring in more than 100 patients treated with this combination has demonstrated that the risk of congestive heart failure is below 10% up to a cumulative epirubicin dose of 990 mg/m2. To examine the possibility that the pharmacokinetic and pharmacodynamic interactions that occur when anthracycline and paclitaxel are administered together might result in subadditive antitumor activity, a phase III study is comparing concomitant vs sequential administration of epirubicin and paclitaxel in patients with advanced breast cancer. A phase I/II study of epirubicin plus docetaxel as first-line chemotherapy for advanced breast cancer patients evaluated the maximum tolerated doses and for subsequent studies recommended epirubicin at 75 mg/m2 plus docetaxel at 80 mg/m2. In the adjuvant setting, an ongoing phase III trial is comparing epirubicin plus paclitaxel vs FEC (fluorouracil, epirubicin, and cyclophosphamide [Cytoxan, Neosar]) in node-positive patients. Preliminary data confirm the cardiac safety of these treatments.

Original languageEnglish
Pages (from-to)21-23
Number of pages3
JournalOncology
Volume15
Issue number5 SUPPL. 7
Publication statusPublished - 2001

Fingerprint

Epirubicin
Breast Neoplasms
docetaxel
Paclitaxel
Cyclophosphamide
Maximum Tolerated Dose
taxane
Anthracyclines
Fluorouracil
Doxorubicin
Heart Failure
Pharmacokinetics
Safety
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Conte, P., Gennari, A., Guarneri, V., Landucci, E., Donati, S., Salvadori, B., ... Baldini, E. (2001). Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials. Oncology, 15(5 SUPPL. 7), 21-23.

Epirubicin/taxane combinations in breast cancer : Experience from several Italian trials. / Conte, Pierfranco; Gennari, Alessandra; Guarneri, Valentina; Landucci, Elisabetta; Donati, Sara; Salvadori, Barbara; Bengala, Carmelo; Orlandini, Cimzia; Baldini, Editta.

In: Oncology, Vol. 15, No. 5 SUPPL. 7, 2001, p. 21-23.

Research output: Contribution to journalArticle

Conte, P, Gennari, A, Guarneri, V, Landucci, E, Donati, S, Salvadori, B, Bengala, C, Orlandini, C & Baldini, E 2001, 'Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials', Oncology, vol. 15, no. 5 SUPPL. 7, pp. 21-23.
Conte P, Gennari A, Guarneri V, Landucci E, Donati S, Salvadori B et al. Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials. Oncology. 2001;15(5 SUPPL. 7):21-23.
Conte, Pierfranco ; Gennari, Alessandra ; Guarneri, Valentina ; Landucci, Elisabetta ; Donati, Sara ; Salvadori, Barbara ; Bengala, Carmelo ; Orlandini, Cimzia ; Baldini, Editta. / Epirubicin/taxane combinations in breast cancer : Experience from several Italian trials. In: Oncology. 2001 ; Vol. 15, No. 5 SUPPL. 7. pp. 21-23.
@article{ce6c8b8c219e496bb6b0ce83834cf1ff,
title = "Epirubicin/taxane combinations in breast cancer: Experience from several Italian trials",
abstract = "Doxorubicinlpaclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90{\%}, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing doxorubicin with epirubicin (Ellence), a less cardiotoxic analog, produced an objective response rate of 84{\%}, but with a low rate of cardiotoxicity. A careful cardiac monitoring in more than 100 patients treated with this combination has demonstrated that the risk of congestive heart failure is below 10{\%} up to a cumulative epirubicin dose of 990 mg/m2. To examine the possibility that the pharmacokinetic and pharmacodynamic interactions that occur when anthracycline and paclitaxel are administered together might result in subadditive antitumor activity, a phase III study is comparing concomitant vs sequential administration of epirubicin and paclitaxel in patients with advanced breast cancer. A phase I/II study of epirubicin plus docetaxel as first-line chemotherapy for advanced breast cancer patients evaluated the maximum tolerated doses and for subsequent studies recommended epirubicin at 75 mg/m2 plus docetaxel at 80 mg/m2. In the adjuvant setting, an ongoing phase III trial is comparing epirubicin plus paclitaxel vs FEC (fluorouracil, epirubicin, and cyclophosphamide [Cytoxan, Neosar]) in node-positive patients. Preliminary data confirm the cardiac safety of these treatments.",
author = "Pierfranco Conte and Alessandra Gennari and Valentina Guarneri and Elisabetta Landucci and Sara Donati and Barbara Salvadori and Carmelo Bengala and Cimzia Orlandini and Editta Baldini",
year = "2001",
language = "English",
volume = "15",
pages = "21--23",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5 SUPPL. 7",

}

TY - JOUR

T1 - Epirubicin/taxane combinations in breast cancer

T2 - Experience from several Italian trials

AU - Conte, Pierfranco

AU - Gennari, Alessandra

AU - Guarneri, Valentina

AU - Landucci, Elisabetta

AU - Donati, Sara

AU - Salvadori, Barbara

AU - Bengala, Carmelo

AU - Orlandini, Cimzia

AU - Baldini, Editta

PY - 2001

Y1 - 2001

N2 - Doxorubicinlpaclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing doxorubicin with epirubicin (Ellence), a less cardiotoxic analog, produced an objective response rate of 84%, but with a low rate of cardiotoxicity. A careful cardiac monitoring in more than 100 patients treated with this combination has demonstrated that the risk of congestive heart failure is below 10% up to a cumulative epirubicin dose of 990 mg/m2. To examine the possibility that the pharmacokinetic and pharmacodynamic interactions that occur when anthracycline and paclitaxel are administered together might result in subadditive antitumor activity, a phase III study is comparing concomitant vs sequential administration of epirubicin and paclitaxel in patients with advanced breast cancer. A phase I/II study of epirubicin plus docetaxel as first-line chemotherapy for advanced breast cancer patients evaluated the maximum tolerated doses and for subsequent studies recommended epirubicin at 75 mg/m2 plus docetaxel at 80 mg/m2. In the adjuvant setting, an ongoing phase III trial is comparing epirubicin plus paclitaxel vs FEC (fluorouracil, epirubicin, and cyclophosphamide [Cytoxan, Neosar]) in node-positive patients. Preliminary data confirm the cardiac safety of these treatments.

AB - Doxorubicinlpaclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing doxorubicin with epirubicin (Ellence), a less cardiotoxic analog, produced an objective response rate of 84%, but with a low rate of cardiotoxicity. A careful cardiac monitoring in more than 100 patients treated with this combination has demonstrated that the risk of congestive heart failure is below 10% up to a cumulative epirubicin dose of 990 mg/m2. To examine the possibility that the pharmacokinetic and pharmacodynamic interactions that occur when anthracycline and paclitaxel are administered together might result in subadditive antitumor activity, a phase III study is comparing concomitant vs sequential administration of epirubicin and paclitaxel in patients with advanced breast cancer. A phase I/II study of epirubicin plus docetaxel as first-line chemotherapy for advanced breast cancer patients evaluated the maximum tolerated doses and for subsequent studies recommended epirubicin at 75 mg/m2 plus docetaxel at 80 mg/m2. In the adjuvant setting, an ongoing phase III trial is comparing epirubicin plus paclitaxel vs FEC (fluorouracil, epirubicin, and cyclophosphamide [Cytoxan, Neosar]) in node-positive patients. Preliminary data confirm the cardiac safety of these treatments.

UR - http://www.scopus.com/inward/record.url?scp=0035344857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035344857&partnerID=8YFLogxK

M3 - Article

C2 - 11396360

AN - SCOPUS:0035344857

VL - 15

SP - 21

EP - 23

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5 SUPPL. 7

ER -